Looks like they found a few targets there. I believe the next trials will be on earlier stage patients and on the identified target cancers. Looking good. From the web site.
"Perth, Australia. 21 June 2006: Solbec Pharmaceuticals (ASX: SBP) is pleased to
announce that the complete results of its Phase I cancer clinical trial of Coramsine® for
the treatment of advanced solid tumours have been presented at the 2006 Annual
Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta Georgia.
These results have also been published in the Journal of Clinical Oncology (Citation:
Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol 24,
No. 18S (June 20 Supplement), 2006: 2070). A link to the abstract has been posted on
Solbec’s website in the “Investor Relations” section.
The complete Phase I results detailed the 2-hour, 4-hour and 24-hour infusion groups,
27 patients in total. No myelosuppression or other serious drug-related toxicity was
recorded and partial responses were documented in three of the eight patients receiving
six or more cycles of Coramsine® therapy ( responses were seen in: renal cell
carcinoma, non-small cell lung cancer and a cancer of unknown primary origin).
Responses were noted using both 2-hour and 4-hour infusions.
ASCO is the world’s leading professional organisation representing physicians who
treat people with cancer. More than 23,000 oncology health care practitioners belong to
ASCO, representing all oncology disciplines. As such, Solbec’s presentation is an
important factor in developing awareness in the world’s specialist medical and scientific
community of Coramsine’s® clinical progress."
SBP
solbec pharmaceuticals limited
